Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer

Summary

This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.

Critical appraisal

This study highlights a clinically relevant resistance mechanism to KRAS G12D inhibitors, a major challenge in PDAC treatment. Acquired resistance to HRS-4642 was observed in a clinical trial (NCT06520488), underscoring the urgency for new strategies. The finding that nimotuzumab can reverse this resistance in synergy with HRS-4642 is highly promising. This combination provides a strong foundation for advancing clinical research, potentially justifying a Phase II or III trial evaluating this dual therapy in PDAC patients with KRAS G12D mutations who have developed resistance. If these results are clinically validated, it could change practice by offering a therapeutic option for patients failing targeted treatment, with a potential clinical impact within 3-5 years.

The summary and the appraisal were written by a language model from the title and abstract of the original article. The article was selected automatically by a model, without human review. Methodology